MedTrace Logo

Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma

NCT07477912 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-03-17

No results posted yet for this study

Summary

The mail purpose of this study is to estimate the safety and the efficacy of anti-BCMA CAR- T cell immunotherapy for adults with relapsed or refractory multiple myeloma

Conditions

  • Multiple Myeloma Refractory

Interventions

BIOLOGICAL

anti BCMA CAR-T cells

Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 50 x 10⁶ to 250 x 10⁶ anti BCMA CAR-T cells

Sponsors & Collaborators

  • Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology

    lead OTHER_GOV

Principal Investigators

  • Mikhail Uss, MD · State Institution Minsk Scientific and Practical Center for Surgery, Transplantology, and Hematology, Minsk, 220087

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2028-02-01
Completion
2030-02-01

Countries

  • Belarus

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07477912 on ClinicalTrials.gov